(Reuters) – Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs. Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision. […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.